InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report) fell 1.6% during trading on Monday . The stock traded as low as C$4.13 and last traded at C$4.19. 17,035 shares traded hands during trading, a decline of 42% from the average session volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Down 1.6 %
The company’s 50 day moving average is C$4.19. The company has a current ratio of 2.13, a quick ratio of 1.45 and a debt-to-equity ratio of 8.48. The stock has a market capitalization of C$33.73 million and a P/E ratio of -2.77.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
Featured Articles
- Five stocks we like better than InMed Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Nordstrom’s Winning Formula: 3 Factors Behind the Stock’s Success
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- How to See Stocks the Way Warren Buffett Sees Stocks
- Business Services Stocks Investing
- 3 No-Brainer Stocks to Buy and Hold Long-Term
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
